Jay Skyler

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

University of Miami (Florida) is a private research university with students from around the world that is focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. The university was founded in 1925 and it is headquartered in Coral Gables, FL.

Moerae Matrix, Inc. is a biotechnology company based in Morristown, NJ. Moerae Matrix, Inc. develops novel therapies as a biotechnology company. The company was founded by Cynthia Lander, who has been the CEO since incorporation.

Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA.

The International Diabetes Federation (IDF) is an umbrella organization of over 240 national diabetes associations in 160 countries and territories. The private company is based in Brussels, Belgium. The mission of IDF is to promote diabetes care, prevention, and a cure worldwide. IDF advocates for people with diabetes and works towards its mission by collaborating with national diabetes associations, healthcare professionals, and policymakers. Founded in 1950, IDF represents the interests of the growing number of people with diabetes and those at risk.